Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504026-19-01

Acronym

ABX-CT-302EU/EAGLE-i

Enrollment

330

Registered

2024-01-12

Start date

2024-06-05

Completion date

Unknown

Last updated

2025-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

Confidential commercial information

Interventions

DRUGRADELUMIN 1300 MBq/ml solution injectable

DRUGRadelumin 1300 MBq/ml oplossing voor injectie

DRUGRADELUMIN 2000 MBq/ml solution injectable

DRUGRadelumin 2000 MBq/mL solución inyectable

DRUGRadelumin 1300 MBq/ml Injektionslösung

DRUGRadelumin 2000 MBq/ml Injektionslösung

DRUGRadelumin 1300 MBq/mL solución inyectable

DRUGRadelumin 2000 MBq/ml oplossing voor injectie

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Confidential commercial information	—

Countries

France, Germany, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026